Why did ACCD's Q3 2025 EPS decline?

The diluted EPS of Accolade for Q3 2025 was -$1.5, which represents a significant decline of 435.71% compared to the same period the previous year. This substantial decrease in EPS can be attributed to several factors:

1. **Revenue Decline**: Although Accolade reported a 5.73% increase in total revenue for Q3 2025, reaching $105.06 million, this growth was not sufficient to offset the negative impact of other factors. It is important to note that the company's revenue growth rate has been slowing down, which could be a contributing factor to the EPS decline.
2. **Net Income Growth**: The net income of Accolade for Q3 2025 was -$121.26 million, representing a substantial decline of 475.69% compared to the same period the previous year. This significant decrease in net income is a direct result of the company's operational performance and can have a disproportionate impact on EPS due to the nature of the calculations.
3. **Economic and Market Conditions**: The decline in EPS may also be influenced by broader economic and market conditions. For instance, the COVID-19 pandemic has disrupted various industries, including healthcare, and has led to increased volatility in the financial markets. These factors can affect a company's financial performance and its ability to generate profits.

In conclusion, the decline in ACCD's Q3 2025 EPS can be attributed to a combination of revenue decline, net income growth, and economic and market conditions.